Alnylam Pharmaceuticals, Inc.

Alnylam Pharmaceuticals, Inc. is a Humankind 100 company whose ranking is based on its Humankind Value, a proprietary metric that provides an estimate of the overall dollar amount a company creates for investors, consumers, employees, and society at large.

Alnylam is a biopharmaceutical company focused on discovering and developing RNA interference therapeutics to treat genetic illnesses.

Ticker: ALNY

Humankind Value: $23.8 B

Revenue: $354.7 M

Market Cap: $16.1 B

(All values are in US Dollars, where M=Million, B=Billion, T=Trillion.)

Healthcare is a central component of our measure of Humankind Value, as a large contribution to modern life expectancies has come from the last 150 years of medical innovation. Alnylam Pharmaceuticals, Inc., though not profitable, has earned a spot among our top 100 Humankind Value companies, in large part due to Healthcare R&D ($22.6 B) and Pharmaceuticals ($1.4 B). The value associated with Healthcare R&D and Pharmaceuticals includes the impact of an estimated 498,016.2 additional years lived by people worldwide. However, there is room for improvement with respect to Greenhouse Gases (-$27.9 M) and Air Pollution (-$5.9 M). Healthcare R&D, Pharmaceuticals, Greenhouse Gases, and Air Pollution are attached to this company as a result of its direct business activities.

How the Humankind Value Methodology Drives the Rankings

We take a quantitative, data-driven approach to estimating the economic impact that companies have on investors, customers, employees, and society at large, rolling social responsibility into a single dollar value that we use to represent what a company is contributing to humanity. As far as we can tell, we're the first ones doing it this way.

LEARN MORE ABOUT OUR RESEARCH
How Methodology Drives the Rankings